Status:
ACTIVE_NOT_RECRUITING
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Lead Sponsor:
BeiGene
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading so...
Eligibility Criteria
Inclusion
- Key Eligibility Criteria :
- Participants must sign a written informed consent form (ICF); and agree to comply with study requirement
- Phase 1a (Dose Escalation):
- Part A, A-CN, and B: Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor previously treated with standard systemic therapy or for whom treatment is not available or not tolerated Note: Only Chinese participants will be eligible for Part A-CN.
- Part C: Participant has histologically or cytologically confirmed, locally advanced, unresectable Stage III Non-small cell lung cancer (NSCLC) suitable for definitive chemoradiotherapy (CRT)
- Part D: Participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinoma (ESCC) suitable for definitive CRT
- Phase 1b (Dose Expansion): Participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy.
- Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumor tissue sample.
- Phase 1a Part A, A-CN, B and Phase 1b: ≥ 1 measurable lesion per Response evaluation criteria in solid tumors (RECIST) v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Key Exclusion Criteria:
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
- Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
- Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s).
- Clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s).
- Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.
- NOTE: Other protocol defined inclusion/exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
July 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2026
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT05381909
Start Date
July 6 2022
End Date
November 1 2026
Last Update
September 22 2025
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner Md Anderson Cancer Center
Gilbert, Arizona, United States, 85234-2165
2
Florida Cancer Specialist (Scri) Sarasota
Sarasota, Florida, United States, 34232
3
Scri Florida Cancer Specialists North
St. Petersburg, Florida, United States, 33705-1449
4
Scri Florida Cancer Specialist East
West Palm Beach, Florida, United States, 33401-3406